

Personal Information

Name Oliver Rath
Nationality Austrian
Date of Birth 4th of September 1974

Profile

- Author/co-author of more than 25 scientific research papers and reviews in Oncology.
- A highly accomplished scientist with more than 15 years' oncological research experience in both the pharmaceutical industry and in Academia.
- Significant expertise in *in vivo* testing, cell and molecular biology, genomics, systems biology, crystallography, medicinal chemistry and large-scale screening.
- Excellent knowledge of the oncology drug discovery market.
- Extensive business experience and contract negotiation in a CRO.

Education

Sep 2005 **Master of Business Administration**
to University of Strathclyde, Graduate School of Business,
Oct 2008 Glasgow, United Kingdom.

Apr 2000 **PhD in Biochemistry**
to University of Vienna,
Jul 2004 Vienna, Austria.

Aug 1998 **Diploma in Biochemistry**
to University of Vienna,
Feb 2000 Vienna, Austria.

Professional Experience

Jun 2016 **Director Business Development Europe & Korea**
to Champions Oncology
present <http://www.championsoncology.com>

Jul 2013 **Business Development/Project Manager**
to Oncotest GmbH, Freiburg, Germany
June 2016 <http://www.oncotest.com>

Sep 2012 **Team Leader Pharmacology**
to Redx Oncology, Liverpool, United Kingdom.
Jun 2013 <http://www.redxoncology.co.uk>

Nov 2011 **Deputy Head**
to RNAi Screening Facility
Aug 2012 Beatson Institute for Cancer Research, Glasgow, United Kingdom.
<http://www.beatson.gla.ac.uk>

Nov 2010 **Principal Scientific Officer**
to Molecular Motors Group, Cancer Research UK
Oct 2011 Beatson Institute for Cancer Research, Glasgow, United Kingdom.

Nov 2009 **Senior Research Scientist**
to Proteomics and Signalling Networks Group, Cancer Research UK,
Oct 2010 Beatson Institute for Cancer Research, Glasgow, United Kingdom.

Nov 2004 **Research Scientist**
to Proteomics and Signalling Networks Group, Cancer Research UK,
Oct 2009 Beatson Institute for Cancer Research, Glasgow, United Kingdom.

Oct 2003 **Research Scientist**
to Department of Obstetrics and Gynecology,
May 2004 University of Vienna, Austria.

Apr 2000 **PhD Student**
to Department of Exploratory Research,
Sep 2003 Boehringer-Ingelheim Austria, Vienna, Austria.
<http://www.boehringer-ingelheim.at>

Aug 1998 **Masters Student**
to Department of NCE Discovery,
Nov 1999 Boehringer-Ingelheim Austria, Vienna, Austria.

Scientific Publications

25. Talapatra S.K., **Rath O.**, Clayton E., Tomasi S. and Kozielski F. (2016) Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis. *J Nat Prod.*, **79**, 1576-1585.
24. Kim H.K., Kim S.Y., Lee S.J., Kang M., Kim S.T., Jang J., **Rath O.**, Schueler J., Lee D.W., Park W.Y., Kim S.J., Park S.H. and Lee J. (2016) BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. *Transl Oncol.*, **9**,197-202.
23. Mardilovich K., Baugh M., Crighton D., Kowalczyk D., Gabrielsen M., Munro J., Lourenco F., James D., Kalna G., McGarry L., **Rath O.**, Shanks E., Garnett M., McDermott U., Brookfield J., Charles M., Hammonds T. and Olson M.F. (2015) LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. *Oncotarget*, **36**, 38469-38486.
22. Lee J.Y., Kim S.Y., Park C., Kim N.K., Jang J., Park K., Yi J.H., Hong M., Ahn T., **Rath O.**, Schueler J., Kim S.T., Do I.G., Lee S., Park S.H., Ji Y.I., Kim D., Park J.O., Park Y.S., Kang W.K., Kim K.M., Park W.Y., Lim H.Y. and Lee J. (2015). Patient-derived cell models as preclinical tools for genome-directed targeted therapy. *Oncotarget*, **28**, 25619-25630.
21. von Thun A., Preisinger C., **Rath O.**, Schwarz J.P., Ward C., Monsefi N., Rodríguez J., Garcia-Munoz A., Birtwistle M., Bienvenut W., Anderson K.I., Kolch W. and von Kriegsheim A. (2013) Extracellular signal-regulated kinase regulates RhoA activation and tumor cell plasticity by inhibiting guanine exchange factor H1 activity. *Mol Cell Biol*, **33**, 4526-4537.
20. Good J.A.D., Wang F., **Rath O.**, Kaan H.Y., Talapatra S.K., Podgorski D., Mackay S.P., Kozielski F. (2013) Optimized S-Trityl-L-Cysteine Based Inhibitors of Kinesin Spindle Protein with potent in Vivo Antitumor Activity in Lung Cancer Xenograft Models. *J Med Chem*, **56**, 1878-1893.
19. Ulaganathan, V., Talapatra, S.K., **Rath, O.**, Pannifer, A.D., Hackney, D.D. and Kozielski, F. (2013) Structural Insights Into a Unique Inhibitor Binding Pocket in Kinesin Spindle Protein, *J Am Chem Soc*, **135**, 2263-2672.
18. **Rath, O.** and Kozielski, F. (2012) Kinesins and cancer, *Nat Rev Cancer*, **12**, 527-539.
17. Abualhasan, M.N., Good, J.A., Wittayanarakula, K., Anthony, N.G., Berretta, G., **Rath, O.**, Kozielski, F., Sutcliffe, O.B. and MacKay, S. (2012) Doing the methylene shuffle – further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine, *Eur J Med Chem*, **54**, 483-498.
16. Zebisch, A., Wölfler, A., Fried, I., Wolf, O., Lind, K., Bodner, C., Haller, M., Drasche, A., Pirkebner, D., Matallanas, D., **Rath, O.**, Blyth, K., Delwel, R., Taskesen, E., Quehenberger, F., Kolch, W., Troppmair, J. and Sill, H., (2012) Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia, *Leukemia*, **26**, 1842-1849.
15. Wang, F., Good, J.A., **Rath, O.**, Kaan H.Y., Sutcliffe, O., MacKay, S. P. and Kozielski, F. (2012) Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity. (2012), *J Med Chem*, **55**, 1511-1525.

14. Al-Mulla, F., Bitar, M.S., Al-Maghrebi, M., Behbehani, A.I, Al-Ali, W., **Rath, O.**, Doyle, B., Tan, K-Y., Pitt, A. and Kolch, W. (2011) Raf Kinase Inhibitor Protein RKIP Enhances Signaling by Glycogen Synthase Kinase-3 β , *Cancer Res*, **71**, 1334-1341.
13. Al-Mulla, F., Bitar, M.S., Taqi, Z., **Rath, O.** and Kolch W. (2011) Raf Kinase Inhibitory Protein (RKIP) modulates cell cycle kinetics and motility, *Mol Biosyst*, **7**, 928-941.
12. Tcherniuk, S., Skoufias, D.A., Labriere, C., Gueritte, F., **Rath, O.**, Guillou, C. and Kozielski, F. (2010) Relocation of Aurora B and Survivin from Centromeres to the Central Spindle Impaired by a Kinesin-Specific MKLP-2 Inhibitor, *Angew Chem Int Ed Engl.*, **49**, 8228-8231.
11. Shin, S-Y., **Rath, O.**, Zebisch, A., Choo, S-M., Kolch W. and Cho, K-H. (2010) The Functional Roles of Multiple Feedback Loops in ERK and Wnt Signaling Pathways that Regulate Epithelial-Mesenchymal Transition, *Cancer Res*, **70**, 6715-6724.
10. Vera, J. *, **Rath, O.***, Balsa-Canto, E. *, Banga, J.R., Kolch, W. and Wolkenhauer, O. (2010) Investigating dynamics of inhibitory and feedback loops in ERK signalling using power-law models. *Mol Biosyst*, **6**, 2174-2191., * equal contribution
9. Kaan H.Y., Ulaganathan, V., **Rath, O.**, Laggner, C., Prokopcová, H., Dallinger, D., Kappe, C.O. and Kozielski F. (2010) Structural Basis for Inhibition of Eg5 by Dihydropyrimidines: Stereoselectivity of Antimitotic Inhibitors Enastron, Dimethylenastron and HPc45, *J Med Chem*, **53**, 5676-5683.
8. Garcia, R.L., Grindlay, G.J., **Rath, O.**, Fee, F. and Kolch W. (2009) Regulation of human myoblast differentiation by hPEBP4. *EMBO Rep*, **10**, 278-284.
7. Shin, S-Y.*, **Rath, O.***, Choo, S-M., Fee, F., McFerran, B., Kolch, W. and Cho, K-H. (2009) Positive and Negative Feedback Regulations Coordinate the Dynamic Behavior of the Ras/Raf/MEK/ERK Signal Transduction Pathway. *J Cell Science*, **122**, 425-235. * equal contribution
6. Nikolov, S., Vera, J., **Rath, O.**, Kolch, W., and Wolkenhauer, O. (2009) The role of inhibitory proteins as modulators of the oscillatory behaviour in the NF- κ B signalling pathway. *IET Systems Biology*, **3**, 2, 59-76.
5. **Rath, O.***, Park, S.* , Tang, H.H., Banfield, M.J., Brady, R.L., Lee, Y.C., Dignam, J.D., Sedivy, J.M., Kolch, W. and Yeung, K.C. (2008) The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. *Cell Signal.*, **20**, 5, 935-941. * equal contribution
4. **Rath, O.**, Himmler, A., Baum, A., Sommergruber, W., Beug, H. and Metz, T. (2007) c-Myc is required for transformation of FDC-P1 cells by EGFRvIII. *FEBS Letters*, **581**, 13, 2549-2556.
3. Dhillon, A.S., Hagan, S., **Rath, O.** and Kolch, W. (2007) MAP kinase signalling pathways in cancer. *Oncogene*, **26**, 22, 3279-3290.

2. Kim, D.*, **Rath, O.***, Kolch, W. and Cho, K-H. (2007) A Hidden Oncogenic Positive Feedback Loop Caused by Crosstalk Between Wnt and ERK Pathways. *Oncogene*, **26**, 4571-4579. * equal contribution

1. Park, S.*, **Rath, O.***, Beach, S., Xiang, X., Kelly, S.M., Luo, Z., Kolch, W. and Yeung, K.C. (2006) Regulation of RKIP binding to the N-region of the Raf-1 kinase. *FEBS Letters*, **580**, 27, 6405-6412. * equal contribution